XETRDMP
Market cap2.12bUSD
Dec 23, Last price
37.80EUR
1D
-0.53%
1Q
12.84%
IPO
40.42%
Name
Dermapharm Holding SE
Chart & Performance
Profile
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 1,135,351 10.79% | 1,024,776 8.68% | 942,912 18.78% | |||||||
Cost of revenue | 522,102 | 443,869 | 402,274 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 613,249 | 580,907 | 540,638 | |||||||
NOPBT Margin | 54.01% | 56.69% | 57.34% | |||||||
Operating Taxes | 45,462 | 83,680 | 84,073 | |||||||
Tax Rate | 7.41% | 14.41% | 15.55% | |||||||
NOPAT | 567,787 | 497,227 | 456,565 | |||||||
Net income | 62,368 -53.54% | 134,236 -35.95% | 209,583 144.20% | |||||||
Dividends | (56,532) | (116,833) | (47,379) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 116,430 | 4,887 | 5,580 | |||||||
Long-term debt | 982,207 | 524,295 | 586,935 | |||||||
Deferred revenue | 9,204 | 9,456 | ||||||||
Other long-term liabilities | 268,325 | 91,269 | 131,289 | |||||||
Net debt | 864,568 | 302,410 | 326,307 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 219,422 | 288,533 | 250,368 | |||||||
CAPEX | (41,541) | (39,014) | (61,203) | |||||||
Cash from investing activities | (415,432) | (99,008) | (129,347) | |||||||
Cash from financing activities | 204,538 | (199,768) | (80,979) | |||||||
FCF | 347,661 | 531,285 | 408,333 | |||||||
Balance | ||||||||||
Cash | 159,542 | 161,358 | 172,061 | |||||||
Long term investments | 74,527 | 65,414 | 94,147 | |||||||
Excess cash | 177,301 | 175,533 | 219,062 | |||||||
Stockholders' equity | 444,258 | 431,702 | 399,044 | |||||||
Invested Capital | 1,705,313 | 863,131 | 941,624 | |||||||
ROIC | 44.21% | 55.10% | 48.76% | |||||||
ROCE | 32.57% | 53.33% | 45.18% | |||||||
EV | ||||||||||
Common stock shares outstanding | 53,840 | 53,840 | 53,840 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 717,836 | 675,816 | 595,797 | |||||||
EV/EBITDA | ||||||||||
Interest | 54,968 | 12,338 | 8,837 | |||||||
Interest/NOPBT | 8.96% | 2.12% | 1.63% |